Concerning the successful modulation of NK cells in vivo, the approach may also be significant for NK-mediated cancer therapy, apart from other conventional regimens (i.e., transfusion of autologous or allogeneic NK cells and even administration of IL-2) [31, 34–36]. The gene discussed is IL2; the disease is cancer.